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The immunopathogenesis of chronic hepatitis C virus (HCV) infection is a matter of great controversy and has 
been suggested to involve a complex balance between cytokines with pro and anti-inflammatory activity. We inves-
tigated the expression of inflammatory cells and cytokines in the liver and serum of 51 chronically HCV infected 
patients and compared them to data from two sets of normal controls: 51 healthy blood donors and 33 liver biopsies 
of healthy liver donors. We also assessed the relationship between selected cytokines and cell populations in hepatic 
compartments and the disease stage. Compared with controls, hepatitis C patients had a greater expression of portal 
TNF-α, TGF-β and CD4+ and acinar IFN-γ, TNF-α, IL-1β and IL-4, as well as a higher serum concentration of IL-2, 
IL-10 and TGF-β. Significant positive correlations were found between portal CD4+ and TNF-α, portal CD8+ and 
TGF-β, portal CD45+RO and TNF-α, acinar CD45+RO and IFN-γ and acinar CD57+ and TGF-β. In conclusion, we 
have shown that (i) in this sample of predominantly mild disease, the immune response was associated with a pro-
inflammatory response pattern, (ii) CD4+ T-lymphocytes played a major role in orchestrating the immune response 
and (iii) these events primarily took place in the portal space.
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Hepatitis C virus (HCV) is a major cause of chronic 
liver disease, with around 130 million people infected 
worldwide, accounting for an estimated 27% of cirrhosis 
cases and 25% of primary haepatocellular carcinoma cas-
es (Alter 2007). Both viral and host immune mechanisms 
are involved in chronic infections, with the spontaneous 
resolution of HCV linked to vigorous and multi-specific 
T-cell responses and to attenuated CD4+ and CD8+ cell 
responses associated with viral persistence (Chang et al. 
2001, Thimme et al. 2001, Day et al. 2002). 
Several studies have suggested that T-cell immuno-
regulatory cytokines play a key role in both HCV viral 
persistence and in the extent of liver damage. Therefore, 
while some cytokines may exert a pro-inflammatory ac-
tivity, such as IL-1 (α and β), IFN-α, IL-8, TNF-α and 
IL-2, which can prime T-cells towards a Th-1 type im-
munity, others have a predominantly anti-inflammatory 
activity, as is the case for IL-4, IL-6 and IL-10, which are 
involved in Th-2 immunity. Additionally, some of these 
cytokines may have a fibrogenic (e.g., TGF-β) or an anti-
fibrogenic (e.g., IFN-α) role (Tilg et al. 2006). Currently, 
it is unclear whether several inflammatory processes are 
the result of pure Th-1 or Th-2 type responses, or, as in 
hepatitis C, both arms (Th1 + Th2) are involved (Brown 
& Neuman 2001). Nevertheless, the expression of some 
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cytokines is more closely related to the severity of the 
disease. IFN-γ is clearly augmented in the serum of 
chronic hepatitis C patients (Tilg et al. 1992, Cacciarelli 
et al. 1996, Kamal et al. 2004) and its increase has been 
correlated with an increase in the severity of disease 
(Gonzalez-Peralta et al. 1994). Moreover, an increased 
expression of IL-1, IL-2, IL-6, IL-10 and IL-18 has been 
documented in either the blood or liver of chronically 
HCV infected patients (Makris et al. 1994, Schvoerer et 
al. 2003, Hassan et al. 1997, Oyanagi et al. 1999, Polyak 
et al. 2001). Nonetheless, most studies have been limited 
by a reduced sample size, resulting in a lack of statistical 
power. Additionally, the great variability in the type of 
patients that were included in the studies, the techniques 
employed for cytokine assessment and the source of the 
specimens (peripheral blood or liver) has made it dif-
ficult to compare their results. 
In this study, we aimed to investigate the immune re-
sponse to HCV through expression of inflammatory cells 
and cytokines in the liver and serum of 51 chronically 
HCV-infected patients compared to normal controls. We 
further assessed the relationship between the selected 
cytokines and cell populations in both the peripheral and 
hepatic compartments with the stage of disease.
PATIENTS AND METHODS
Patients and controls - Patients were consecutively 
recruited from the Infectious Diseases Division at the 
University Hospital from March 2001-October 2002. 
Most of the patients were referred from the blood bank 
service of the hospital. All of the patients underwent a 
complete medical and laboratory evaluation and a liver 
biopsy. The inclusion criteria for this study was as fol-
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lows: (i) an age between 18-60 years, (ii) a confirmed 
HCV infection (by a second or third-generation ELISA 
or immunoblot technique), (iii) a positive qualitative PCR 
for HCV-RNA, (iv) a 1.54-4.00 fold increase in serum 
alanine aminotransferase (ALT) and (v) a liver biopsy 
confirming chronic hepatitis, graded and staged accord-
ing to Ishak et al. (1995). Patients with any other hepatic 
diseases, previous immunosuppressive treatment, HIV or 
human T cell lymphotropic virus infection, or concurrent 
malignant disease were excluded. Two sets of controls 
were selected for this study; healthy blood donors were 
selected for cytokine pattern comparisons and liver biop-
sy specimens from the organ donors were used as controls 
for immunohistochemistry features. The institutional re-
view board approved the study and all of the patients and 
blood donors provided written informed consent.
Virological markers - Quantification of HCV-RNA 
was performed with an Amplicor HCV Monitor (Roche 
Diagnostic Systems, Mannheim, Germany) at a lower de-
tection limit of 600 IU/mL. Genotyping was carried out 
by using the purified product of the nested-PCR, as de-
limited by NCR4 primers. The samples were submitted to 
sequencing (ABI Prism DNA Sequencer) using the ABI 
Prism Big Dye Terminator Cycle Sequencing Ready Re-
action version 2.0 (Applied Biosystems). The sequences 
were then analysed and compared with compatible geno-
types within the HCV Sequence Data Base with BLAST 
(Basic Local Alignment Search Tool, 2003).
Tissue sample processing - The biopsy specimens, 
obtained during a routine diagnosis of the patients at the 
University Hospital, were fixed in 10% formalin and em-
bedded in paraffin for light microscopy. Only the biopsy 
specimens measuring at least 1 cm or bearing at least 
10 portal spaces were analyzed. The specimens were 
then submitted to haematoxylin-eosin staining, as well 
as Masson’s trichromate, reticulin and Perls’ techniques. 
Two experienced histopathologists independently per-
formed all of the analyses. The case specimens were 
then graded and staged according to the semi-quantita-
tive Ishak score (Ishak et al. 1995). 
Immunohistochemistry - Expression of cytokines 
in the biopsy specimens of HCV-cases and liver donor 
controls was semi-quantitatively assessed through im-
munomarking by immunohistochemistry, following the 
streptavidin-biotin-peroxidase immunohistochemical 
method of detection. The following specific monoclonal 
antibodies were employed: IFN-γ (MAB285), TNF-α 
(AF-210-NA), IL-1α (AF-200-NA), IL-1 β (AF-201-NA), 
IL-2 (AF-202-NA), IL-4 (AF-204-NA), IL-6 [AF-206-
NA and IL-10 (MAB217) (all from R&D Systems)] 
and transforming growth factor (TGF)-β (MCA 797; 
SEROTEC). Cell subpopulations were assessed with 
the following specific monoclonal antibodies: mouse 
anti-CD45+RO (M742), mouse anti-CD4 (M834), mouse 
anti-CD8 (M7103), mouse anti-CD68 (M876), rabbit 
anti-S100 (Z311) (all from DAKO) and mouse anti-CD57 
(1166 CH; IMMUNOTECH).
The sections were dewaxed in xylene and hydrated 
through a graded ethanol series. After this, 3% hydrogen 
peroxide was used to block endogenous peroxidase. The 
sections were incubated overnight with primary mouse 
antibodies and the streptavidin-biotin-peroxidase im-
munohistochemical method of detection was used. The 
Catalysed Signal Amplification-CSA, based on the per-
oxidase catalysed deposition of a biotinylated phenolic 
compound, was used to better visualise the positive 
cells. Biotinylated anti-mouse antibody was applied to 
the sample for 15 min at 37ºC, following application of 
the primary antibodies. Peroxidase-labelled streptavi-
din-biotin complex was then applied for 15 min at 37ºC, 
followed by the biotinyl tyramide reagent for 15 min and 
a secondary reaction with streptavidin peroxidase. The 
slides were counterstained with Harris haematoxylin 
and 3.3 diamino-benzidine tetrahydrochloride (SIGMA 
Chemical Company) was used as chromogen.
Counting of the cytokines and cell populations was 
performed with an optical microscope and a square op-
tical grid (1 cm2). Screening began at the first portal 
space on the left upper extremity and then moved to the 
right and downwards, with the grid sequentially centred 
on each portal space and the surrounding area. Within 
each screening square, positive cells were counted in 
the portal and the periportal spaces at a 400X magnifi-
cation. At least 5-10 portal spaces were counted on each 
slide. The number of positive cells was divided by the 
number of counted spaces and this result was divided by 
0.0625 (Weibel 1979). 
Cytokine assay - A quantitative measurement of se-
rum cytokines was performed for the cases and blood 
donor controls using a commercially available enzyme-
linked immunosorbent assay (R&D Systems), according 
to the manufacturer’s instructions. The following cyto- 
kines were assessed: IL-1α, IL-2, IL-4, IL-6, IL8, IL-10, 
TNF-α, TNF-β, IFN-γ and TGF-β. The minimum detec-
tion limit was 10 pg/mL; thus, any measures below this 
threshold were considered to be zero.
Statistical analysis - For descriptive analyses, the 
means and standard deviations, or the medians and in-
terquartile ranges, are reported. Comparisons of propor-
tions between the cases and controls were assessed by 
Chi-square test or Fisher’s exact test, when appropriate. 
Continuous and ordinal data were compared by Mann-
Whitney rank sum test. The Spearman’s rank correlation 
coefficient was used to assess correlations between the 
continuous variables. A significance level of 0.05 was 
used and all of the p values are two-sided. All of the 
analyses were conducted in SPSS version 12 (2002). 
RESULTS
Characteristics of the cases and controls - Fifty-one 
HCV-patients were included in the study and compared 
with 51 healthy blood donors and 33 liver donors. The 
demographic and epidemiological characteristics of the 
cases and controls are shown in Table I. Thirty (58.8%) 
cases were male, with a median age of 38 years (range 
20-59). The cases and controls did not differ significantly 
with regard to gender, age or race. For 41 cases, the mean 
disease duration from exposure to biopsy was available 
and was 18.2 years (range 3-31).
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The detailed laboratory and histological findings of 
the cases are listed in Table II. In summary, the median 
aspartate aminotransferase and ALT levels were 45 IU/L 
(range 30-197) and 69 IU/L (range 32-399), respectively; 
11 patients (21.5%) had hypoalbuminaemia and 16 pa-
tients (31.4%) had hypergammaglobulinaemia. The ma-
jority of patients (76.5%) were infected with HCV geno-
type 1 and 59.2% had an HCV RNA viral load greater 
than 850.000 IU/mL.
The median Ishak score for histology was 5 (range 
3-14) and a minimal and mild disease accounted for 
78.4% of the pathologic findings (31.4% and 47.1%, re-
spectively). Confluent hepatocyte necrosis was not seen. 
Grade I fibrosis (F1) was seen in 30 cases (58.8%) and 
portal inflammation was found in 29 (56.8%) cases. All 
of the cases had Councilman bodies in the hepatic pa-
renchyma and the hepatic sinusoids presented with mild 
hyperplasia and hypertrophy in Kupffer cells, with a 
predominance of lymphocyte infiltrates.
The majority (78%) of cases showed some evidence 
of steatosis, which was either mild, moderate or severe, 
either focused or generalized and either macro or micro-
vacuolar. Biopsies from the liver donor biopsies showed 
no evidence of pathologic findings. A mild haemosid-
erin deposition and glycogenic degeneration was seen in 
one and two samples, respectively.
Cytokine patterns in the cases and blood donor con-
trols - Compared with the blood donor controls (Table 
III), the cases had significantly higher serum levels of 
IL-2 (426 ± 362 vs. 91 ± 124 pg/mL; p < 0.01), IL-10 (294 
± 289 vs. 38 ± 141 pg/mL; p < 0.01), TNF-β (17 ± 35 vs. 7 
± 11 pg/mL; p < 0.01) and TGF-β (898 ± 348 vs. 1 ± 904 
pg/mL; p < 0.01). On the other hand, the cases showed 
significant lower levels of the following cytokines: IL-4 
(27 ± 21 vs. 62 ± 93 pg/mL; p = 0.02), IL-6 (11 ± 30 vs. 48 
± 69 pg/mL; p < 0.01), IL-8 (58 ± 84 vs. 263 ± 337 pg/mL; 
p < 0.01) and IFN-γ (4 ± 9 vs. 26 ± 73 pg/mL; p < 0.01). 
Cell populations and cytokine patterns in liver bi-
opsies of the cases and liver donor controls - In immu-
nohistochemistry reactions, the positive cytokines and 
cell populations were stained brown, as shown in Figs 
1, 2, respectively. The cell populations from the cases 
TABLE I
Demographic characteristics of chronically hepatitis C virus (HCV) infected cases and controls
 Cases Blood donors Liver donors
Variable n = 51 n = 51 n = 33
Male gender - n (%) 30 (58.8) 28 (54.9) 15 (45.5)
Age years - median (range)  38 (20-59) 33 (18-58) 36 (18-60)
White race - n (%) 34 (66.7) 36 (70.6) 21 (63.6)
Risk factors   
History of injection drug abuse  3 (5.9) NA NA
Previous transfusion  21 (41.2) NA NA
Previous surgery  27 (52.9) NA NA
Duration of HCV infectiona 18.2 (3-31) – –
a: available for 41 patients and defined as time in years from suspected exposure to biopsy; NA: not available. 
TABLE II
Biochemical, virological and histological characteristics  
of 51 cases
Variable n (%) or median (range)
Serum ALT (IU/L) 88.2 (32-399)
Serum AST (IU/L) 59.3 (30-197)
Total leukocytes (per mm3) 6,200 (3.300-13.800)
Platelets (per mm3) 214,764 (50.000-352.000)
Albumin (g/dL) 4.2 (2.7-5.1)
Gammaglobulin (g/dL) 1.56 (0.7-2.6)
HCV genotypes  
1a 10 (19.6)
1b 29 (56.8)
2a 1 (2.0)
2b 1 (2.0)
3a 10 (19.6)
Ishak score (overall) 5 (3-14)
Fibrosis stage  1 (0-6)
F1-F4 42 (82.3)
F5-F6 9 (17.7)
Portal inflammation 2 (0-4)
1-2 40 (78.4)
3-4 11 (21.6)
Periportal inflammation 1 (0-4)
0-1 44 (86.3)
2-3 7 (13.7)
Focal inflammation 1 (0-4)
0-1 47 (92.2)
2 4 (7.8)
ALT: alanine aminotransferase; AST: aspartate aminotrans-
ferase; HCV: hepatitis C virus. 
had a higher expression of portal CD4+ (706.4 ± 388.0 
vs. 294.5 ± 129.2 cells/mm2; p < 0.01) and CD8+ (196.8 ± 
113.8 vs. 66.3 ± 57.8 cells/mm2; p < 0.01) than the con-
trols (Table IV).
The cytokine patterns of the cases had a higher ex-
pression of acinar IL-4 (2.5 ± 2.0 vs. 1.1 ± 1.2 cells/mm2; 
p < 0.01), TNF-α (3.8 ± 2.8 vs. 0.9 ± 1.6 cells/mm2; p < 
0.01), IFN-γ (3.1 ± 5.2 vs. 1.5 ± 2.3 cells/mm2; p < 0.01) 
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and TGF-β (5.1 ± 3.9 vs. 1.7 ± 1.4 cells/mm2; p < 0.01), 
compared to the controls. The cases also expressed signif-
icantly higher portal TNF-α (3.6 ± 3.0 vs. 1.6 ± 2.5 cells/
mm2; p < 0.01) and TGF-β (3.6 ± 3.8 vs. 0.8 ± 1.4 cells/
mm2; p < 0.01) than the controls. The cases showed a sig-
nificantly lower expression of portal S100 dendritic cells 
(DC) (22.5 ± 20.2 vs. 64.8 ± 42.3 cells/mm2; p < 0.01), ac-
inar S100 (2.3 ± 4.7 vs. 8.5 ± 7.6 cells/mm2; p < 0.01), ac-
inar IL-1β (0.2 ± 0.5 vs. 0.8 ± 1.1 cells/mm2; p < 0.01) and 
acinar IL-10 (1.3 ± 1.6 vs. 2.7 ± 2.7 cells/mm2; p < 0.01).
Correlation patterns of cell population and cytokines 
among cases - The correlations between the cell markers 
and cytokines was analysed at either the portal spaces or 
the acinar areas (Table V). Significant positive correla-
tions were seen between the following measures at the 
portal spaces: CD45+RO and TNF-α, CD4+ and TNF-α, 
CD8+ and TGF-β, CD68+ and TNF-α, CD57+ and IL-10, 
S-100 and IL-10. At the acinar level, CD45+ and IFN-γ, 
TABLE III
Cytokine profiles in peripheral blood of chronically hepatitis 
C virus (HCV) infected cases and healthy blood donors
 Cases Blood donors
 n = 51 n = 51
Cytokine mean (SD) mean (SD) p value
IL-2 426.373 (361.594) 90.636 (123.531)  < 0.01
IL-10 294.444 (289.346) 37.744 (140.680)  < 0.01
TNF-β 16.804 (34.935) 6.866 (10.858) < 0.01
TGF-β 897.553 (347.819) 1.334 (904) < 0.01
IL-1α 1.280 (3.325) 5.640 (21.594) < 0.01
IL-4 27.178 (20.612) 61.583 (92.659) 0.02
IL-6 10.742 (30.466) 47.593 (69.181) < 0.01
IL-8 57.817 (84.190) 262.941 (336.897) < 0.01
IFN-γ 4.187 (9.217) 25.569 (73.028) < 0.01
TNF-α 64.437 (149.211) 24.473 (41.016) 0.07
SD: standard deviations. 
Fig. 1: typical staining of immunohistochemistry detection of cytok-
ines: A: IFN-γ in acinar area (400X); B: IFNγ in portal space; C: IL2 
in acinar area; D: IL6 in acinar area. Arrows indicate cells staining 
positive for the marker.
Fig. 2: typical staining of immunohistochemistry detection of cell 
populations. A: CD4 T-lymphocytes in acinar area (400X); B: CD4 
T-lymphocytes in portal areas (200X); C: S100 cells in portal space 
(400X); D: CD45+ cells in acinar area (400X). Arrows indicate cells 
staining positive for the marker.
TABLE IV
Cell populations and cytokine patterns in liver biopsy of 
chronically hepatitis C virus (HCV) infected cases  
and liver donors
 Cases  Liver donors
 n = 51 n = 33
Variable mean (SD)  mean (SD) p value
Portal CD45 412.3 (290.9) 304.5 (111.8) 0.20
Acinar CD45 33.1 (35.7) 38.2 (30.8) 0.07
Portal CD4 706.4 (388.0) 294.5 (129.2) < 0.01
Acinar CD4  46.4 (33.0) 36.7 (23.2) 0.15
Portal CD8 196.8 (113.8) 66.3 (57.8) < 0.01
Acinar CD8 12.5 (13.2) 13.8 (17.2) 0.55
Portal CD68 107.4 (106.9) 64.5 (42.7) 0.12
Acinar CD68 104.6 (65.6) 92.4 (38.6) 0.70
Portal S100 22.5 (20.2) 64.8 (42.3) < 0.01
Acinar S100 2.3 (4.7) 8.5 (7.6) < 0.01
Portal CD57 24.3 (33.9) 12.5 (10.3) 0.39
Acinar CD57 11.1 (10.4) 6.4 (3.8) 0.07
Portal TNF-α 3.6 (3.0) 1.6 (2.5) < 0.01
Acinar TNF-α 3.8 (2.8) 0.9 (1.6) < 0.01
Portal TGF-β 3.6 (3.8) 0.8 (1.4) < 0.01
Acinar TGF-β 5.1 (3.9) 1.7 (1.4) < 0.01
Portal INF-γ 3.1 (5.2) 1.5 (2.3) 0.14
Acinar INF-γ 2.8 (2.8) 0.5 (1.2) < 0.01
Portal IL-1α 1.1 (1.9) 0.6 (1.4) 0.28
Acinar IL-1α 0.3 (0.7) 0.6 (2.0) 0.67
Portal IL-1β 1.3 (2.6) 0.7 (1.2) 0.74
Acinar IL-1β 0.2 (0.5) 0.8 (1.1) < 0.01
Portal IL-2 1.0 (2.2) 0.9 (2.2) 0.78
Acinar IL-2 1.7 (1.8) 1.5 (2.0) 0.45
Portal IL-4 1.7 (2.8) 0.8 (1.3) 0.06
Acinar IL-4 2.5 (2.0) 1.1 (1.2) < 0.01
Portal IL-6 0.2 (0.6) 0.0 (0.3) 0.36
Acinar IL-6 0.7 (1.5) 0.8 (1.0) 0.17
Portal IL-10 0.5 (1.1) 0.5 (1.2) 0.57
Acinar IL-10 1.3 (1.6) 2.7 (2.7) < 0.01
SD: standard deviations. 
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CD45+ and IL-1α, CD57+ and TGF-β and CD57+ and IL-2 
were positively correlated, while CD68+ and IL-6 and 
CD68+ and IL-10 were negatively correlated.
The correlations between the degree of liver dam-
age and the cell populations and cytokines were also as-
sessed. In immunohistochemistry analyses of the cases, 
periportal activity was positively correlated with portal 
CD4+ expression (r = 0.4; p < 0.01), while focal inflam-
mation was positively correlated with acinar CD4+ (0.33; 
p = 0.02). A significant positive correlation for cytokine 
density was found between periportal hepatitis and por-
tal IL-1β (r = 0.36; p < 0.01) and between acinar activity 
and acinar TGF-β (r = 0.34; p = 0.02). Following a corre-
lation analysis of the serum cytokines and the degree of 
liver lesions, IL-8 was positively correlated with fibrosis 
(r = 0.29; p = 0.04) and IL1-α was negatively correlated 
with focal inflammation (r = -0.29; p = 0.04); the other 
serum cytokines did not show any correlation with liver 
compromised liver (data not shown).
DISCUSSION
In this study, we systematically assessed the role of 
a comprehensive array of cytokines and cell populations 
in chronically HCV infected patients and compared them 
with normal controls. Among the cases, we found that 
there was a greater expression of portal TNF-α, TGF-β, 
CD4+ and CD8+ and acinar IFN-γ, TNF-α, TGF-β and 
IL-4, as well as a higher serum concentration of IL-2, 
IL-10 and TGF-β compared to the controls. 
Cytokines are key mediators of inflammation, apop-
tosis, necrosis and fibrosis and they are actively involved 
in the regeneration process of liver tissue after injury. It 
has been hypothesised that successful treatment of hepa-
titis C depends on a complex balance between pro and 
anti-inflammatory responses (Bertoletti et al. 1997, Tsai 
et al. 2003, Wan et al. 2009). In our study, we found both 
pro and anti-inflammatory responses, with a predomi-
nant pro-inflammatory response pattern in the liver 
mediated by IFN-γ and TNF-α and modulated by CD4+, 
CD8+ and CD45RO+ T lymphocytes. This complex bal-
ance is further supported by the significant correlations 
found between: (i) portal CD4+ and TNF-α, (ii) portal 
CD8+ and TGF-β, (ii) portal CD45+RO and TNF-α and 
(iv) acinar CD45+RO and IFN-γ. The latter correlations 
that involve CD45+RO suggest that there is an ongoing 
activation of the cellular immune response, which is in 
agreement with the study by Murata et al. (2002). 
In line with other reports (Minutello et al. 1993, Sakai 
et al. 1999, Exley et al. 2002), our results demonstrate 
the compartmentalised nature of the immune response 
to HCV. The correlation between periportal activity and 
portal CD4+, as seen in a preliminary study (Viso et al. 
TABLE V
Correlations between cell populations and cytokine patterns by immuhohistoquemistry in liver biopsy of  
chronically hepatitis C virus (HCV) infected cases
Cell Citokines 
populations  Portal TNF-α Acinar TNF-α Portal TGF-β Acinar TGF-β Portal IFN-γ Acinar IFN-γ
Portal CD45  rs 0.32 NA 0.06 NA 0.08 NA
 p 0.023a NA 0.692 NA 0.592 NA
Acinar CD45  rs NA 0.00 NA -0.08 NA 0.29
 p NA 0.992 NA 0.562 NA 0.042a
Portal CD4  rs 0.40 NA 0.10 NA 0.12 NA
 p 0.004a NA 0.496 NA 0.407 NA
Acinar CD4 rs NA -0.09 NA 0.23 NA -0.17
 p NA 0.514 NA 0.107 NA 0.220
Portal CD8  rs 0.00 NA 0.30 NA 0.13 NA
 p 0.994 NA 0.030a NA 0.354 NA
Acinar CD8  rs NA -0.06 NA 0.04 NA -0.01
 p NA 0.697 NA 0.796 NA 0.932
PortalCD68  rs 0.29 NA 0.04 NA 0.07 NA
 p 0.042a NA 0.797 NA 0.635 NA
Acinar CD68  rs NA 0.17 NA 0.17 NA 0.20
 p NA 0.241 NA 0.227 NA 0.166
Portal S100  rs 0.09 NA -0.06 NA 0.04 NA
 p 0.540 NA 0.689 NA 0.766 NA
Acinar S100  rs NA 0.03 NA -0.10 NA 0.04
 p NA 0.854 NA 0.478 NA 0.768
Portal CD57  rs -0.28 NA 0.17 NA 0.06 NA
 p 0.049a NA 0.224 NA 0.688 NA
Acinar CD57  rs NA -0.13 NA 0.29 NA -0.26
 p NA 0.358 NA 0.040a NA 0.064
a: significant p values; NA: not applicable; rs: r-squared. 
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2007) and the increased expression of portal TNF-α and 
acinar IFN-γ, TNF-α and IL-4, which was not replicated 
in serum, suggests that there was an intra-hepatic re-
sponse. Apparently, most of the immune response oc-
curred at the portal space level, supported by the lack 
of correlation between the hepatic and serum cytokines 
among the cases. 
TNF-α production is an early event in the pathogen-
esis of liver damage, triggering the synthesis of other 
cytokines. It is required for the proliferation of normal 
hepatocytes in liver regeneration, but it also mediates 
hepatocyte death (Zhu et al. 1998). The increased ex-
pression of portal and acinar TNF-α and acinar IFN-γ 
in the cases compared to the controls reinforces the ma-
jor role of these pro-inflammatory cytokines in the liver 
disease caused by HCV. 
IL-2 is considered to be a Th1 type cytokine and is 
involved in enhancing the proliferation and activation of 
most T-lymphocytes, NK cells and B-lymphocytes. Liver 
sinusoidal and inflammatory cells have been reported to 
be sources of IL-2 and no consensus exists on the pre-
dictive value of this cytokine. Apparently, expression 
of IL-2 is associated with a more advanced stage of dis-
ease, as previously reported (Makris et al. 1994, Napoli 
et al. 1996, Bozkaya et al. 2000, Gramenzi et al. 2005). 
In our sample, although a higher concentration of IL-2 
was found in the serum, no significant expression was 
found in the liver from the cases compared to the normal 
controls. This could possibly be due to the relatively mild 
disease that was observed in most of our cases, agree-
ing with reports from other authors (Woitas et al. 1997, 
Falasca et al. 2006). Indeed, it has been hypothesised that 
failure to secrete IL-2 might lead to a disruption of IFN-γ 
and proliferative capacity, contributing to the develop-
ment of a persistent infection (Semmo et al. 2005). Our 
findings agree with those of Gramenzi et al. (2005), who 
reported that there was an inverse correlation between 
ALT levels and IL-2 expression when cytokine profiles 
of patients with chronic disease were compared with pa-
tients who had persistently normal serum ALT levels. 
IL-6 is a major mediator of the inflammatory process 
in the acute phase response, acting as a blocker of cell 
apoptosis (Baumann & Gauldie 1990) and promoting the 
differentiation of naïve T-cells into Th1 cells. IL-6 has 
been associated with disease progression and has been 
reported to be elevated in both hepatic and peripheral 
compartments (Malaguarnera et al. 1997, Oyanagi et al. 
1999, Lapinski et al. 2001, Falaska et al. 2006). Interest-
ingly, in this study, IL-6 was not associated with either 
chronic HCV infection or with the stage of disease. Our 
results are in contrast to those of other researches, but 
agree with those of Cribier et al. (1998), who found simi-
lar patterns in serum IL-6 between HCV-infected and 
non-infected patients. Although, it should be noted that 
IL-6 was above the cut-off value in only 11 patients, pos-
sibly due to the overall lower severity of disease sample. 
However, these findings deserve further investigation 
with appropriately powered studies.
TGF-β has been implicated as a mediator of hepatic 
fibrogenesis and is known to have negative regulatory 
effects on the immune system (Nakatsukasa et al. 1990, 
Nelson et al. 1997, Roulot et al. 1999, Sakaguchi et al. 
2002). In this study, expression of TGF-β was signifi-
cantly higher in both the liver (portal space and lobule) 
and peripheral compartments of the cases compared to 
the controls. These findings confirm those of other au-
thors (Flisiak et al. 2000, Kinnman et al. 2000, Ray et al. 
2003) and provide additional evidence that TGF-β acts 
as an immune mediator in chronic HCV infection. 
The negative correlation of S100 DC with peri-portal 
activity among the cases and its lower expression com-
pared to the controls suggests that there was a lack of 
HCV recognition by these cells, which, in turn, might 
have facilitated viral persistence. The mechanisms in-
volved in this down regulation are still unclear and a 
few hypotheses have been raised. It has been suggested 
that HCV proteins might modulate T-cell responses by 
decreasing the stimulatory ability of DC (Sarobe et al. 
2003) and that there would be an allostimulatory defect 
of monocyte-derived DC because these cells would con-
stitute an extra-hepatic reservoir for the virus (Bain et 
al. 2001). Jinushi et al. (2004) also suggested that the 
aberrant expression of natural killer (NK) receptors as-
sociated with chronic infection might have an impact on 
the magnitude and direction of DC activation of T-cells. 
The positive correlation between portal S100 cells and 
IL-10 in our study reinforces this hypothesis. IL-10 has 
a modulatory effect on hepatic fibrogenesis by down-
regulating the pro-inflammatory response, including the 
antigen-presenting cells and in a controlled study, IL-10 
has also been shown to reduce liver damage (Nelson et 
al. 2000, 2003). Studies have reported that disease pro-
gression is associated with an increased expression of 
circulating IL-10 (Gramenzi et al. 2005), a correlation 
with low liver alterations (Piazzolla et al. 2000) and a 
decreased expression at intrahepatic compartments (Na-
poli et al. 1996). In our study, the cases had higher serum 
concentrations of IL-10, but lower intrahepatic expres-
sion, than did the respective controls, thus reinforcing 
the predominance of pro-inflammatory factors. 
The possible correlations between the duration of 
infection (n = 41 patients, whose duration of infection 
could be estimated) or the age of the patient (n = 51) with 
the immunological parameters was also analysed but did 
not reveal any biologically meaningful correlations (data 
not shown). The only possibly relevant finding was the 
observation that age was positively correlated with por-
tal CD45+RO (p = 0.012, r = 0.35) (as expected), as well 
as with acinar CD8+ (p = 0.020, r = 0.33), but was nega-
tively correlated with acinar IL-10 (p = 0.024, r = -0.32). 
Therefore, the duration of the infection or the age of the 
patient is unlikely to explain our findings.
Our study has some limitations. Firstly, it is possible 
that the observed balance towards a pro-inflammatory 
type of response was biased by the inclusion of cases 
with a milder disease; only ~20% presented a more se-
vere classification (F5-F6). For our study, we split the 
patients into two groups: one group containing the nine 
patients with severe histology (F5-F6) and the other 
group containing the 42 patients with mild histology 
(F1-F4). We then reassessed the correlation analyses 
of the liver data (cytokine and immunohistochemistry) 
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and blood (cytokines) and we did not find any statisti-
cal differences between the two groups in any of the 
comparisons (data not shown). Also, the data from the 
42 patients remained similar to the data from all of the 
patients (n = 51) (data not shown). Secondly, the cross-
sectional nature of the study precludes causal inferences 
and a prospective assessment of these cases is warrant-
ed. However, our results devise several hypotheses for 
future research. Thirdly, genetic polymorphisms associ-
ated with cytokine expression have been shown to play a 
role in the ability to respond to therapy (Yee et al. 2001, 
Milton et al. 2005) and were not assessed in our study. 
Fourth, the function of T lymphocytes was not analysed 
in this study as it has been in other studies (Moonka et 
al. 2008). Finally, some comparisons might have been 
affected by a lack of statistical power, particularly those 
with a considerable floor effect that was caused by the 
lower limit of detection for the cytokine assays. 
In conclusion, we simultaneously assessed pro and 
anti-inflammatory related cytokines and cell populations 
in the liver and sera and have shown that (i) the immune 
response in the samples of predominantly mild disease 
was associated with several pro-inflammatory cytok-
ines, (ii) CD4+ T-lymphocytes played a major role in or-
chestrating the immune response and (iii) these events 
took place primarily at the portal space. Our results sug-
gest that this balance is highly dynamic, particularly in 
less severe disease and further research is needed to ex-
plore the longitudinal aspects of this relationship.
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